Overview
BIAF market data
Price History
BIAF price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$8.66 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.10 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -280.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.46 – $13.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.1M · P/B 0.73 · P/S 0.55.
Company News
bioAffinity Technologies shares are trading lower after the company announced pricing of $4 million private placement offering priced at-the-market under Nasdaq rules.Benzinga · Aug 13, 2026, 6:21 PM
bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M EstimateBenzinga · Aug 7, 2026, 12:11 PM
bioAffinity Announces Publication Of Clinical Review And White Paper For Incorporating CyPath Lung Into Pulmonary Nodule Evaluation And Cancer SurveillanceBenzinga · Jul 27, 2026, 12:10 PM
bioAffinity, Pictor Collaborate To Integrate Flow Cytometry And Proteomic Analysis Platform To Analyze Immune Cell Populations And Cytokine Profiles Related To Airway InflammationBenzinga · Jul 22, 2026, 12:11 PM
BioAffinity Technologies Announces 200% Sales Growth YoY For CyPath Lung Cancer DiagnosticBenzinga · Jul 7, 2026, 12:55 PM
bioAffinity To Present Preclinical Findings For Therapeutic Approach That Uses siRNAs That Kill Squamous And Basal Skin Cancer Cells In Vitro At 2026 RNA Therapeutics SymposiumBenzinga · Jun 22, 2026, 12:10 PM
bioAffinity Technologies Prices $3.2M Offering Of 4M Shares (Or Pre-funded Warrants) At $0.80/Share ($0.793/Warrant)Benzinga · Jun 17, 2026, 1:30 PM
bioAffinity Receives Mexican Institute Of Industrial Property Allowance For A Patent Application Regarding Methods Of Predicting The Likelihood Of Lung Cancer Using Flow CytometryBenzinga · May 27, 2026, 12:07 PM